Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Cerilliant
UBS
Express Scripts
Argus Health
Colorcon
Dow
Farmers Insurance

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,114,319

« Back to Dashboard

Which drugs does patent 6,114,319 protect, and when does it expire?

Patent 6,114,319 protects DUREZOL and is included in one NDA.

Protection for DUREZOL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has six patent family members in five countries.
Summary for Patent: 6,114,319
Title: Compositions containing difluprednate
Abstract:The present invention relates to a liquid composition comprising difluprednate, oil, water and an emulsifier. The composition of the present invention has superior antiinflammatory action and antiallergic action. The composition of the present invention shows superior transfer to a lesion and uniform drug distribution upon administration, as compared to conventional preparations containing difluprednate, so that it shows sufficient efficacy in a smaller dose. The inventive composition is associated with extremely less uncomfortable feeling and foreign sensation upon administration, as compared to conventional preparations containing difluprednate, and it can be administered easily to local sites of eye, nose, ear and the like.
Inventor(s): Kimura; Masako (Kakogawa, JP), Yasueda; Shin-ichi (Kobe, JP), Yamaguchi; Masazumi (Kobe, JP), Inada; Katsuhiro (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (JP) Mitsubishi Chemical Corporation (JP)
Application Number:09/076,124
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,114,319
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Drugs Protected by US Patent 6,114,319

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp DUREZOL difluprednate EMULSION;OPHTHALMIC 022212-001 Jun 23, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,114,319

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-124415May 14, 1997

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Chinese Patent Office
Chubb
Mallinckrodt
US Army
Fuji
Cantor Fitzgerald
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.